Syndax Pharmaceuticals, Inc.

NASDAQ:SNDX

Biotechnology

Healthcare
$8.56 +0.66%

+$0.13 today

Market cap
$770.64M
Beta
0.39
P/E (TTM)
-6.8
EPS (TTM)
-$2.81
52W Low $8.59High $25.59

Volume 3.46M

Average 1.70M

SNDX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Syndax Pharmaceuticals, Inc.NASDAQ: SNDX

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin holds steady near 95.9%

Gross margin was 95.9% in Q1 FY2026, up 0.4 pp from a year earlier. On a trailing-twelve-month basis it was 98.0%, down 0.0 pp year over year.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
95.9%-6.4 pp QoQ
Last fiscal yearDec 2025
96.0%-0.6 pp YoY
LTMMar 2026
98.0%-0.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.4 pp——
1 year-0.6 pp——
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
96.0%
Year-over-year change
-0.6pp

Gross Margin vs competitors

How SNDX compares with its peers on the latest reported figures

  • SNDX's LTM Mar 2026 gross margin of 98.0% is the 2nd highest of the 8 companies compared; the peer median is 86.5%.
  • Its year-over-year change of -0.0 pp is the 4th highest of 8, against a peer median of -0.7 pp.
SNDX Competitors Peer median
Gross Margin for SNDX and competitors
Company Period LTM level YoY 3-year change
CTMXCytomX Therapeutics, Inc.LTM Mar 202699.3% -0.7 pp+0.0 pp
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 202698.0% -0.0 pp—
RCUSArcus Biosciences, Inc.LTM Jun 202694.0% -6.0 pp-4.0 pp
NUVBNuvation Bio Inc.LTM Jun 202693.9% +66.4 pp—
NRIXNurix Therapeutics, Inc.LTM Aug 202686.5% +249.4 pp+455.2 pp
MGNXMacroGenics, Inc.LTM Mar 202669.9% +7.9 pp-24.0 pp
ZYMEZymeworks Inc.LTM Sep 202668.6% -31.4 pp+0.0 pp
XNCRXencor, Inc.LTM Jun 202643.3% -18.0 pp+112.9 pp
REPLReplimune Group, Inc.FY2025— ——
ORICORIC Pharmaceuticals, Inc.FY2025— ——
ALXOALX Oncology Holdings Inc.FY2025— ——
Peer median (excluding SNDX) 86.5%-0.7 pp+0.0 pp

Competitors are the stored peer set for SNDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue139.71M0023.68M172.35M
Cost of Revenue000826K6.97M
Gross Profit139.71M0022.85M165.38M
Gross Margin100.0%——96.5%96.0%
Research & Development88.25M118.5M163.03M241.65M258.78M
Selling, General & Admin25.24M33.26M66.92M120.88M179.68M
Operating Expenses113.49M151.76M229.95M362.53M438.47M
Depreciation & Amortization43K33K12K8K6K
EBITDA26.87M(146.17M)(209.14M)(313.82M)(251.63M)
EBITDA Margin19.2%——-1325.3%-146.0%
Operating Income26.22M(151.76M)(229.95M)(339.67M)(273.08M)
Operating Margin18.8%——-1434.4%-158.4%
Interest Income403K5.87M21.16M26.09M22.73M
Interest Expense1.9M3.14M208K4.93M33.79M
Other Income / Expenses(1.29M)2.42M20.59M20.91M(12.34M)
Income Before Tax24.93M(149.34M)(209.36M)(318.76M)(285.42M)
Pre-Tax Margin17.8%——-1346.1%-165.6%
Income Tax Expense00000
Net Income24.93M(149.34M)(209.36M)(318.76M)(285.42M)
Net Margin17.8%——-1346.1%-165.6%
EPS (Basic)0.48(2.46)(2.98)(3.73)(3.29)
EPS (Diluted)0.48(2.46)(2.98)(3.73)(3.29)
Weighted Avg Shares52.06M60.76M70.37M85.62M86.63M
Weighted Avg Shares (Diluted)52.06M60.76M70.37M85.62M86.63M

Syndax Pharmaceuticals, Inc.

NASDAQ:SNDX

Intrinsic Alpha fair value

Locked

Current Price

$8.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.